Copy/Paste the core content from the latest edited report brochure. DELETE the “Market Outlook” header from the top.
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice. Pharmacological treatment includes rate control therapy (e.g., beta blockers, calcium channel blockers, digoxin) and anticoagulation therapy (e.g., vitamin K antagonists, direct-acting oral anticoagulants [DOACs]). Novel agents being investigated in clinical trials to treat AF include Anthos Therapeutics’ abelacimab, Bayer’s asundexian, Janssen’s milvexian, and ARCA’s bucindolol. We expect some of these drugs to launch during our forecast period and fulfill some of the unmet needs that remain in AF. Unmet needs include superior efficacy and safety / tolerability of antiarrythmic drugs, as bradycardia is an important safety concern in AF patients, and superior safety of anticoagulant drugs for stroke prevention in AF.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.